Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

NCT00753545 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: AZD2281
DRUG: matching placebo

Sponsor

AstraZeneca